phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"phgenomics-159Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫCURRENT REVIEWКашель и ангионевротический отёк на фоне приёма ингибиторов ангиотензинпревращающего фермента: генетические маркёрыCough and angioedema from angiotensin-converting enzyme inhibitors: genetic markersДанцевИ. С.DantsevI. S.

г. Москва

СиницинаИ. И.SinitsinaI. I.

г. Москва

СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич — д.м.н., профессор, зав. кафедрой клинической фармакологии и терапии.

г. Москва

dimasychev@mail.ruГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава РоссииРоссияRussian State Academy of Postgraduate EducationRussian Federation20152403202002913Copyright © Данцев И.С., Синицина И.И., Сычёв Д.А., 20202020Данцев И.С., Синицина И.И., Сычёв Д.А.Dantsev I.S., Sinitsina I.I., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/159

В то время как кашель остаётся наиболее частым нежелательным явлением (НЯ) при приёме иАПФ, ангионевротический отёк, уступая ему в частоте, по праву считается наиболее грозным осложнением со стороны данной группы препаратов. Риск развития подобных осложнений, как правило, связан с повышением уровня брадикинина и его активных метаболитов вследствие ингибирования АПФ. Одну из ведущих ролей среди факторов, ассоциированных с уровнем АПФ в плазме и частотой развития осложнений, играют генетические. Для поиска ряда генетических маркёров, как правило, применяется кандидатное картирование. При данном методе проводят анализ связи НЯ с полиморфизмом генов. Данный обзор рассматривает взаимосвязь полиморфизмов в генах-кандидатах с частотой развития НЯ со стороны иАПФ. Кроме того, обсуждаются возможные причины развития изолированного висцерального ангионевротического отёка.

While coughing remains the most frequent adverse drugs reaction (ADR) when taking ACE inhibitors, angioedema giving him a frequency is considered to be the most threatening complication from this group of drugs. The risk of such complications are usually associated with increased levels of bradykinin and it`s active metabolites by inhibiting ACE. Genetic factors associated with the level of ACE in plasma and the incidence of complications play a leading role. To search for genetic markers usually used mapping candidate. This method allows analyzing ADR due to gene polymorphism. The present review consider the relationship of polymorphisms in candidate genes with the frequency of ADR of the ACE inhibitor. In addition, we discuss the possible causes of isolated visceral angioedema.

ангионевротический отёккашельвисцеральная больингибиторы ангиотензинпревращающего ферментанеблагоприятные реакциифармакогенетикаangioedemacoughvisceral painangiotensin-converting enzyme inhibitorsdrug-related side effects and adverse reactionspharmacogeneticsReferencesBrown N.J., Vaughan D.E. Angiotensin-Converting Enzyme Inhibitors. // Circulation. 1998;97:1411-14-20.Brown N.J., Vaughan D.E. Angiotensin-Converting Enzyme Inhibitors. // Circulation. 1998;97:1411-14-20.Орлов В.А., Гиляревский С.Р., Урусбиева Д.М., Даурбекова Л.В. Влияние побочных эффектов иАПФ на тактику лечения сердечно-сосудистых заболеваний. // Рос. Кардиологический жур.-2005-№3.Орлов В.А., Гиляревский С.Р., Урусбиева Д.М., Даурбекова Л.В. Влияние побочных эффектов иАПФ на тактику лечения сердечно-сосудистых заболеваний. // Рос. Кардиологический жур.-2005-№3.Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with angiotensinconverting enzyme inhibitor therapy. A review of the literature and pathophysiology. // Ann Intern Med Aug 1 1992;117(3):234—42.Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with angiotensinconverting enzyme inhibitor therapy. A review of the literature and pathophysiology. // Ann Intern Med Aug 1 1992;117(3):234—42.Eck S.L., Morse J.H., Janssen D.A., Emerson S.G., Markovitz D.M. Angioedema presenting as chronic gastrointestinal symptoms. // Am J Gastroenterol Mar 1993;88(3):436—9.Eck S.L., Morse J.H., Janssen D.A., Emerson S.G., Markovitz D.M. Angioedema presenting as chronic gastrointestinal symptoms. // Am J Gastroenterol Mar 1993;88(3):436—9.Shahzad G., Korsten M.A., Blatt C., Motwani P. Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report. // Mt Sinai J Med Dec 2006;73(8):1123—5.Shahzad G., Korsten M.A., Blatt C., Motwani P. Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report. // Mt Sinai J Med Dec 2006;73(8):1123—5.CKB. Tissue specific autoantibodies induced by captopril. // Clin Res 1987;35:922A.CKB. Tissue specific autoantibodies induced by captopril. // Clin Res 1987;35:922A.Bork K., Dewald G. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. // Am J Med May 1 2004;116(9):644.Bork K., Dewald G. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. // Am J Med May 1 2004;116(9):644.Chase M.P., Fiarman G.S., Scholz F.J., MacDermott R.P. Angioedema of the small bowel due to an angiotensin-converting enzyme inhibitor. // J Clin Gastroenterol Oct 2000;31(3):254—7.Chase M.P., Fiarman G.S., Scholz F.J., MacDermott R.P. Angioedema of the small bowel due to an angiotensin-converting enzyme inhibitor. // J Clin Gastroenterol Oct 2000;31(3):254—7.Molinaro G., Cugno M., Perez M., et al. Angiotensin-converting enzyme inhibitorassociated angioedema is characterized by a slower degradation of des-arginine (9)-bradykinin. // J Pharmacol Exp Ther Oct 2002;303(1):232—7.Molinaro G., Cugno M., Perez M., et al. Angiotensin-converting enzyme inhibitorassociated angioedema is characterized by a slower degradation of des-arginine (9)-bradykinin. // J Pharmacol Exp Ther Oct 2002;303(1):232—7.Pellacani A., Brunner H.R., Nussberger J. Plasma kinins increase after angiotensinconverting enzyme inhibition in human subjects. // Clin Sci (Lond) Nov 1994;87(5):567—74.Pellacani A., Brunner H.R., Nussberger J. Plasma kinins increase after angiotensinconverting enzyme inhibition in human subjects. // Clin Sci (Lond) Nov 1994;87(5):567—74.Lu B., Figini M., Emanueli C., Geppetti P., Grady E.F., Gerard N.P., et al. The control of microvascular permeability and blood pressure by neutral endopeptidase. // Nat Med. 1997; 3:904—907. [PubMed:9256283].Lu B., Figini M., Emanueli C., Geppetti P., Grady E.F., Gerard N.P., et al. The control of microvascular permeability and blood pressure by neutral endopeptidase. // Nat Med. 1997; 3:904—907. [PubMed:9256283].Kopp U.C., Farley D.M., Smith L.A. Bradykinin-mediated activation of renal sensory neurons due to prostaglandin-dependent release of substance P. // Am J Physiol. 1997; 272:R2009—R2016.[PubMed: 9227622].Kopp U.C., Farley D.M., Smith L.A. Bradykinin-mediated activation of renal sensory neurons due to prostaglandin-dependent release of substance P. // Am J Physiol. 1997; 272:R2009—R2016.[PubMed: 9227622].Blais C.J., Rouleau J.L., Brown N.J., Lepage Y., Spence D., Munoz C., et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. // Immunopharmacology. 1999; 43:293—302. [PubMed: 10596866].Blais C.J., Rouleau J.L., Brown N.J., Lepage Y., Spence D., Munoz C., et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. // Immunopharmacology. 1999; 43:293—302. [PubMed: 10596866].Duan Q.L., Nikpoor B., Dube M.P., Molinaro G., Meijer I.A., Dion P., et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. // Am J Hum Genet. 2005; 77:617—626. [PubMed: 16175507].Duan Q.L., Nikpoor B., Dube M.P., Molinaro G., Meijer I.A., Dion P., et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. // Am J Hum Genet. 2005; 77:617—626. [PubMed: 16175507].Bouchard L., Faucher G., Tchernof A., Deshaies Y., Lebel S., Hould F.S., et al. Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals. // Acta Diabetol. 2009; 46:13—21. [PubMed:18682883].Bouchard L., Faucher G., Tchernof A., Deshaies Y., Lebel S., Hould F.S., et al. Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals. // Acta Diabetol. 2009; 46:13—21. [PubMed:18682883].Cui J., Melista E., Chazaro I., Zhang Y., Zhou X., Manolis A.J., et al. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. // J Hypertens. 2005; 23:55—62. [PubMed:15643125].Cui J., Melista E., Chazaro I., Zhang Y., Zhou X., Manolis A.J., et al. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. // J Hypertens. 2005; 23:55—62. [PubMed:15643125].Seneviratne C., Ait-Daoud N., Ma J.Z., Chen G., Johnson B.A., Li M.D. Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. // Neuropsychopharmacology. 2009; 34:2442—2449. [PubMed: 19553914].Seneviratne C., Ait-Daoud N., Ma J.Z., Chen G., Johnson B.A., Li M.D. Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. // Neuropsychopharmacology. 2009; 34:2442—2449. [PubMed: 19553914].Weidinger S., Gieger C., Rodriguez E., Baurecht H., Mempel M., Klopp N., et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. // PLoS Genet. 2008; 4:e1000166. [PubMed: 18846228].Weidinger S., Gieger C., Rodriguez E., Baurecht H., Mempel M., Klopp N., et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. // PLoS Genet. 2008; 4:e1000166. [PubMed: 18846228].Sleiman P.M., Flory J., Imielinski M., Bradfield J.P., Annaiah K., Willis-Owen S.A., et al. Variants of DENND1B associated with asthma in children. // N Engl J Med. 2010; 362:36—44. [PubMed:20032318].Sleiman P.M., Flory J., Imielinski M., Bradfield J.P., Annaiah K., Willis-Owen S.A., et al. Variants of DENND1B associated with asthma in children. // N Engl J Med. 2010; 362:36—44. [PubMed:20032318].Суворов Н.В., Чельцов В.В., Илларионова Т.С, Астахова А.В., Коровякова Э.А. Ингибиторы ангиотензинпревращающего фермента: неблагоприятные побочные реакции. // Вестник РУДН, серия Медицина 2004 №3(27).Суворов Н.В., Чельцов В.В., Илларионова Т.С, Астахова А.В., Коровякова Э.А. Ингибиторы ангиотензинпревращающего фермента: неблагоприятные побочные реакции. // Вестник РУДН, серия Медицина 2004 №3(27).Rigat B., Hubert C., Corvol P., Soubrier F. PCR detection of the incertion/deletion polymorphism of the human ACE gene (DCP1) (dipeptidyl carboxypeptidase 1). // Nucl. Acids Res. 1990. V.20. P.1433.Rigat B., Hubert C., Corvol P., Soubrier F. PCR detection of the incertion/deletion polymorphism of the human ACE gene (DCP1) (dipeptidyl carboxypeptidase 1). // Nucl. Acids Res. 1990. V.20. P.1433.Banerji A.S., Clark M. Blanda, F. LoVecchio, B. Snyder, and C. A. Camargo Jr. 2008. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. // Ann. Allergy Asthma Immunol. 100:327—332.Banerji A.S., Clark M. Blanda, F. LoVecchio, B. Snyder, and C. A. Camargo Jr. 2008. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. // Ann. Allergy Asthma Immunol. 100:327—332.Samuel Michael Lipski, Georges Casimir, Martine Vanlommel1, Mathieu Jeanmaire & Pierre Dolhen. Angiotensin-converting enzyme inhibitorsinduced angioedema treated by C1 esterase inhibitor concentrate (Berinert): about one case and review of the therapeutic arsenal. // Clinical Case Reports 2015; 3(2): 126—130.Samuel Michael Lipski, Georges Casimir, Martine Vanlommel1, Mathieu Jeanmaire & Pierre Dolhen. Angiotensin-converting enzyme inhibitorsinduced angioedema treated by C1 esterase inhibitor concentrate (Berinert): about one case and review of the therapeutic arsenal. // Clinical Case Reports 2015; 3(2): 126—130.Korniyenko A., Alviar C.L., Cordova J.P., Messerli F.H. Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. // Cleve Clin J Med 2011; 78(5): 297_304.Korniyenko A., Alviar C.L., Cordova J.P., Messerli F.H. Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. // Cleve Clin J Med 2011; 78(5): 297_304.Toh S., et al. Comparative risk for angioedema associated with the use of drugs that target the rennin-angiotensin-aldosterone system. // Arch. Intern. Med. 2012;172:1582-1589.Toh S., et al. Comparative risk for angioedema associated with the use of drugs that target the rennin-angiotensin-aldosterone system. // Arch. Intern. Med. 2012;172:1582-1589.Brown N.J., Snowden M., Griffin M.R. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. // JAMA. 1997;278:232-233.Brown N.J., Snowden M., Griffin M.R. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. // JAMA. 1997;278:232-233.Beltrami L., Zanichelli A., Zingale L., Vacchini R., Carugo S., Cicardi M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. // J. Hypertens. 2011;29:2273-2277.Beltrami L., Zanichelli A., Zingale L., Vacchini R., Carugo S., Cicardi M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. // J. Hypertens. 2011;29:2273-2277.Fitzharris P., Jordan A. Investigating recurrent angioedema. // BMJ. 2011;343:d6607.Fitzharris P., Jordan A. Investigating recurrent angioedema. // BMJ. 2011;343:d6607.Coelho M.L., Amaral R., Curvo-Semedo L., Caseiro-Alves F. Small bowel angioedema induced by angiotensin converting enzyme (ACE) inhibitor: US and CT fi ndings. // JBR-BTR. 2014 Jul-Aug;97(4):239-41.Coelho M.L., Amaral R., Curvo-Semedo L., Caseiro-Alves F. Small bowel angioedema induced by angiotensin converting enzyme (ACE) inhibitor: US and CT fi ndings. // JBR-BTR. 2014 Jul-Aug;97(4):239-41.Cohen N., Sharon A., Golik A., Zaidenstein R., Modai D. Hereditary angioneurotic edema with severe hypovolemic shock. // J Clin Gastroenterol Apr 1993;16(3):237—9.Cohen N., Sharon A., Golik A., Zaidenstein R., Modai D. Hereditary angioneurotic edema with severe hypovolemic shock. // J Clin Gastroenterol Apr 1993;16(3):237—9.Ежова Г.П., Бабаев А.А., Новиков В.В. Биоинформационные аспекты протеомики и деградации белка. // Учебно-методические материалы/ Нижний Новгород 2007.Ежова Г.П., Бабаев А.А., Новиков В.В. Биоинформационные аспекты протеомики и деградации белка. // Учебно-методические материалы/ Нижний Новгород 2007.Kostis J.B., Packer M., Black H.R., Schmieder R., Henry D., Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. // Am J Hypertens. 2004; 17:103—111. [PubMed: 14751650].Kostis J.B., Packer M., Black H.R., Schmieder R., Henry D., Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. // Am J Hypertens. 2004; 17:103—111. [PubMed: 14751650].Prashanth M. Thalanayar, Ibrahim Ghobrial, Fritz Lubin, Reena Karnik, and Robin Bhasin. Drug-induced visceral angioedema. // Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260.Prashanth M. Thalanayar, Ibrahim Ghobrial, Fritz Lubin, Reena Karnik, and Robin Bhasin. Drug-induced visceral angioedema. // Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260.Woodard-Grice A.V., Lucisano A.C., Byrd J.B., Stone E.R., Simmons W.H., Brown N.J. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. // Pharmacogenet Genomics. 2010; 20:532-536.Woodard-Grice A.V., Lucisano A.C., Byrd J.B., Stone E.R., Simmons W.H., Brown N.J. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. // Pharmacogenet Genomics. 2010; 20:532-536.Guillaume Parea, Michiaki Kuboj, James B. Byrde, Catherine A. McCartyf, Alencia Woodard-Griceg, Koon K. Teob, Sonia S. Anandc,d, Rebecca L. Zuvichh, Yuki Bradfordh, Stephanie Rossa, Yusuke Nakamurak, Marylyn Ritchiei, and Nancy J. Browng. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. // Pharmacogenet Genomics. 2013 September; 23(9): 470—478. doi: 10.1097/FPC.0b013e328363c137.Guillaume Parea, Michiaki Kuboj, James B. Byrde, Catherine A. McCartyf, Alencia Woodard-Griceg, Koon K. Teob, Sonia S. Anandc,d, Rebecca L. Zuvichh, Yuki Bradfordh, Stephanie Rossa, Yusuke Nakamurak, Marylyn Ritchiei, and Nancy J. Browng. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. // Pharmacogenet Genomics. 2013 September; 23(9): 470—478. doi: 10.1097/FPC.0b013e328363c137.Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R., et al. The kinasemTOR regulates the differentiation of helper T cells through the selective activation of signalingby mTORC1 and mTORC2. // Nat Immunol. 2011; 12:295—303.Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R., et al. The kinasemTOR regulates the differentiation of helper T cells through the selective activation of signalingby mTORC1 and mTORC2. // Nat Immunol. 2011; 12:295—303.

The authors declare that there are no conflicts of interest present.